The median ages of patients whose tumor tissue contained mutations of KRAS, PIK3CA and NRAS (54.5, 58.0 and 56.0 years, respectively) were lower than that of patients containing all-wild types of KRAS, BRAF, PIK3CA and NRAS (median age, 64.0 years). The gene discussed is KRAS; the disease is neoplasm.